Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

What to look forward to in GaBI Journal, 2021, Issue 2 / Professor Philip D Walson, MD

Original Research

Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers / Shalini Harikrishnan, BSc; Ka-Liong Tan, DPhil; Kar Ming Yee, BPharm; Alia Shagari Ahmad Shukri, MSc; N Ramana Reddy, MBBS; Chewy Wuei Leong, PhD

Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation / Kelly Canham, BSc Hons; Claire Newcomb, MSc

Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching / Mansour Somaily, MD; Hana Alahmari, MD; Wejdan Abbag; Shahenda Yousif, MD; Nawar Tayfour, MD; Nouf Almushayt; Saleh Alhusayni, MD; Saeed Almajadiah, MD

Variation in the prices of oncology medicines across Europe and the implications for the future / Brian Godman, BSc, PhD; Steven Simoens, MSc, PhD; Amanj Kurdi, BSc, PhD; Gisbert Selke; John Yfantopoulos; Andrew Hill, PhD, et al.

Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study / Pieter J Glerum, MSc; Mert Hayta, PharmD, MSc; David M Burger, PharmD, PhD; Cees Neef, PharmD, PhD; Marcel L Bouvy, PharmD, PhD; Marc Maliepaard, PhD

Review Articles

A critical review of substitution policy for biosimilars in Canada / Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP

The EU regulatory network and emerging trends – a review of quality, safety and clinical development programmes / Marta Zuccarelli, PharmD; Benjamin Micallef, PharmD; Mark Cilia, PharmD; Anthony Serracino-Inglott, PharmD; Professor John-Joseph Borg, PhD

An overview of the current status of follow-on biologicals in Iran / Farhang Rezaei, PharmD; Nassim Anjidani, PharmD

Microbiological, scientific and regulatory perspectives of hand sanitizers  / Adjunct Associate Professor Sia Chong Hock, BSc Pharm, MSc; Tan Ying Ting, BSc Pharm (Hons); Associate Professor Chan Lai Wah, BSc Pharm (Hons)


Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD

Pilot Study

Use of biologicals in dermatology – following the agreed path or going off-piste? A brief report / Michael Wilcock, MPhil; Andrew Pothecary, MSc

Research News

Biosimilar epoetin for cancer and chemotherapy-induced anaemia in the US

Abstracted Scientific Content

Repurposing non-oncology drugs for cancer treatment / GaBI Journal Editor

An IPRP survey of the regulatory requirements for the waiver of in vivo bioequivalence studies of generic products in certain dosage forms / Alfredo García Arieta, PhD

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Last update: 2021-09-10 Go Back Print

Comments are closed.